Target intelligence / Profile preview

Ankyrin repeat domain 26 pseudogene (No established abbreviation for therapeutic contexts; research DBs may use ANKRD26P (but this often refers to family members or variants, not specifically ENSG00000270402))

Target: No established abbreviation for therapeutic contexts; research DBs may use ANKRD26P (but this often refers to family members or variants, not specifically ENSG00000270402)
Molecular classification: Pseudogene

Overview

Ankyrin repeat domain 26 pseudogene refers to a genomic DNA sequence similar to the coding ANKRD26 gene, but with disabling mutations that render it unable to encode a functional protein. Pseudogenes are remnants of once-functional genes arising from duplication, retrotransposition, or mutation events. Although some rare pseudogenes have regulatory or RNA-level functions, the primary feature of pseudogenes, including ankyrin repeat domain 26 pseudogene, is the lack of an encoded active protein product and absence from established lists of drug targets or receptors.

Other names: ANKRD26P (potential database abbreviation, non-canonical for clinical/therapeutic use)Ankyrin repeat domain 26 pseudogene 1 (for the closely related ANKRD26P1)

Mechanism of action

None (not targetable by drugs; does not encode a functional protein or receptor)

Biological functions

None described for protein-coding or receptor activity (pseudogenes by definition do not encode functional proteins)Some pseudogenes can influence gene regulation via transcriptional interference, RNA-mediated regulation, or act as miRNA decoys—these functions are rare and not well-established for this specific locus

Disease associations

No direct disease roles as a therapeutic targetIn broader genetic association studies, some ankyrin repeat domain pseudogenes are mentioned in cancer or cardiac disorders, but evidence for direct involvement or utility as a biomarker is lacking and generally not clinically relevant

Safety considerations

None reported in any therapeutic or clinical context (as this is not a drug target)

Interacting drugs

None (no known drugs interact with this pseudogene; pseudogenes are not druggable)

Biomarkers

None established for patient selection or efficacy monitoring

Beyond the preview

Go deeper on Ankyrin repeat domain 26 pseudogene (No established abbreviation for therapeutic contexts; research DBs may use ANKRD26P (but this often refers to family members or variants, not specifically ENSG00000270402)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ankyrin repeat domain 26 pseudogene (No established abbreviation for therapeutic contexts; research DBs may use ANKRD26P (but this often refers to family members or variants, not specifically ENSG00000270402)).

Explore the full profile